

## MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

### ERENUMAB FOR PREVENTING MIGRAINE, NICE TA682, MARCH 2021

**RED – RECOMMENDED FOR RESTRICTED USE in Secondary Care**

Name: generic (trade)	What it is	Licensed indications	Decision status	NICE guidance
ERENUMAB s/c injection (Aimovig®▼)	Analgesic; CGRP antagonist; recombinant humanised monoclonal antibody	Prophylaxis of migraine in adults who have at least four migraine days per month	Final	NICE TA682 – recommended

#### MSEMOC recommendation:

Erenumab is recommended as an option for preventing migraine in adults in accordance with NICE technology appraisal recommendations and the [MSEMOC adult headache pathway](#).

#### [NICE TA682](#) recommendation:

1.1 Erenumab is recommended as an option for preventing migraine in adults, only if:

- they have 4 or more migraine days a month
- at least 3 preventive drug treatments have failed\*\*
- the 140 mg dose of erenumab is used and
- the company provides it according to the commercial arrangement.

1.2 Stop erenumab after 12 weeks of treatment if:

- in episodic migraine (less than 15 headache days a month) the frequency does not reduce by at least 50%
- in chronic migraine (15 headache days a month or more with at least 8 of those having features of migraine) the frequency does not reduce by at least 30%.

1.3 These recommendations are not intended to affect treatment with erenumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

\*\*At least three preventative drug treatments should be in line with those included in the [MSEMOC adult headache pathway](#).

For further information refer to the [Summary of Product Characteristics for erenumab](#).

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

<b>References</b>	NICE TA682: Erenumab for preventing migraine: <a href="https://www.nice.org.uk/guidance/ta682">https://www.nice.org.uk/guidance/ta682</a>
<b>Acknowledgements</b>	Mid and South Essex CCGs Medicines Management Teams
<b>Version</b>	1.0
<b>Author</b>	HCPMSEMOC working group
<b>Approved by</b>	MSEMOC; MSE Joint Committee
<b>Date Approved</b>	May 2021; May 2021
<b>Review Date</b>	May 2026 or sooner if subject to any new updates nationally